Cognitive Decline in Chronic Migraine with Nonsteroid Anti-inflammation Drug Overuse: A Cross-Sectional Study

Table 2

Headache characteristic of cases.

	CM		MO
	CM-MOH	CMwoMOH
Headache years, mean ± SD^a	22.67 ± 12.27	17.40 ± 10.68	12.54 ± 9.08
VAS, mean ± SD^b	9.05 ± 1.24	7.30 ± 1.95	7.71 ± 1.51
Duration, day, mean ± SD^c	1.05 ± 1.15	1.51 ± 0.78	1.63 ± 1.01
Headache frequency, days/month, median (IQR)^d	30 (20–30)	20 (15–30)	3 (1–4)
Dosage, pills/attack, median (IQR)^e	3 (2–6)	1 (0–1)	1 (0–1)
Analgesic frequency, days/month, median (IQR)^e	30 (20–30)	1.5 (0–4.5)	1 (0–3)

^aANOVA, CM-MOH vs. MO, ; CM-MOH vs. CMwoMOH, CMwoMOH vs. MO, . ^bANOVA, CM-MOH vs. CMwoMOH, CM-MOH vs. MO, ; CMwoMOH vs. MO, . ^cANOVA, . ^dKruskal–Wallis tests, ; pairwise comparison with adj. sig., CM-MOH vs. MO, CMwoMOH vs. MO, ; CM-MOH vs. CMwoMOH, . ^eKruskal–Wallis tests, ; pairwise comparison with adj. sig., CM-MOH vs. CMwoMOH, CM-MOH vs. MO, ; CMwoMOH vs. MO, ; CM, chronic migraine; CM-MOH, chronic migraine with medication overuse headache; CMwoMOH, chronic migraine without medication overuse headache; MO, migraine without aura; SD, standard deviation; IQR: interquartile range; ANOVA, one-way analysis of variance.